Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuPharma reports positive results from Phase IIb lupus study
During the course of its Phase IIb study an interim analysis was performed and reviewed by an independent data monitoring committee according to ICH guidelines. This analysis was
During the course of its Phase IIb study an interim analysis was performed and reviewed by an independent data monitoring committee according to ICH guidelines. This analysis was
The assessment was based on clinical trials involving more than 2,600 patients, which confirmed the safety and efficacy of Azzalure. This announcement is part of the partnership established
King Pharmaceuticals has reported positive results from its Phase III 12-month open-label safety and efficacy study evaluating Embeda extended release capsules. The results showed that Embeda provided continued
For the fourth quarter ended December 31, 2008, Sangamo reported a consolidated net loss of $2.6 million, or $0.06 per share, against a net loss of $6.7 million,
Pfizer has discontinued a Phase III study of its investigational agent axitinib for the treatment of advanced pancreatic cancer. Based on an interim analysis, an independent Data Safety
RSDecon, a business of Bracco Diagnostics, and Counter Terrorism Solutions have received approval for the importation and use of RSDL chemical warfare agent skin decontamination lotion from the
Roche has announced that it intends to commence a cash tender offer for all outstanding publicly held shares of Genentech at $86.50 per share. Roche, which currently owns
GE Healthcare and Medipattern confirmed their plans to collaborate by signing a definitive collaboration agreement. Medipattern will leverage technology developed in its Cadenza algorithm platform and extend it
The product, Staccato fentanyl (AZ-003/EN-3284), has completed Phase I clinical testing and will be returned to Alexza. In 2007, Endo licensed exclusive rights to develop and commercialize AZ-003
Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design, medicinal chemistry, assay development, in vitro screening, drug metabolism